Title:
METHODS OF TREATING PSYCHIATRIC DISORDERS IN OBESE PATIENTS WITH BREXPIPRAZOLE
Document Type and Number:
WIPO Patent Application WO/2023/141634
Kind Code:
A3
Abstract:
The present disclosure relates to methods of initiating brexpiprazole treatment in patients with schizophrenia or major depressive disorder. In embodiments, an increased dose (relative to the usual dose) is administered to said patients during treatment initiation. The present disclosure further relates to modified dosing regimens for patients that are obese and/or CYP2D6 poor metabolizers. The inventors have discovered that the pharmacokinetics of brexpiprazole are substantively different in obese patients. Consequently, dosing changes are required when initiating treatment with brexpiprazole to achieve the same clinical response: effective treatment of schizophrenia and major depressive disorder. Prior to this invention, the standard of care left such obese patients untreated or undertreated, delaying resolution of their condition.
More Like This:
| WO/2005/012257 | INDAZOLE DERIVATIVES |
| JP2020506192 | Piperazine derivatives to inhibit influenza virus |
| WO/2002/057254 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY |
Inventors:
SRINIVASAN SUNDAR (US)
CHOW WALLEN CHRISTINA (US)
CHOW WALLEN CHRISTINA (US)
Application Number:
PCT/US2023/061104
Publication Date:
September 21, 2023
Filing Date:
January 23, 2023
Export Citation:
Assignee:
LAKE OHARA LLC (US)
International Classes:
A61K31/496; A61K45/06; A61P25/18; A61K9/48; A61P25/24
Domestic Patent References:
| WO2020018136A1 | 2020-01-23 | |||
| WO2022146462A1 | 2022-07-07 |
Other References:
ANONYMOUS: "REXULTI", RXLIST, 6 December 2021 (2021-12-06), XP093093717, Retrieved from the Internet [retrieved on 20231020]
Attorney, Agent or Firm:
COUSIN, Jonathan et al. (US)
Download PDF:
Previous Patent: MODIFIED CELLS AS MULTIMODAL STANDARDS FOR CYTOMETRY AND SEPARATION
Next Patent: HER3 LIGANDS AND USES THEREOF
Next Patent: HER3 LIGANDS AND USES THEREOF